Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors Academic Article uri icon

Overview

MeSH Major

  • Neoplasms
  • Xenograft Model Antitumor Assays

abstract

  • Integration of PDX models as a preclinical platform for assessment of drug efficacy may allow a higher success-rate in critical end points of clinical benefit.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5834154

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdx416

PubMed ID

  • 28945830

Additional Document Info

start page

  • 2595

end page

  • 2605

volume

  • 28

number

  • 10